NCT07077161
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07077161
Title Cabozantinib Dose Skipping as an Alternative to Dose Reductions (SKIPPY 2)
Acronym SKIPPY 2
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors dr. Tom van der Hulle
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD

Facility Status City State Zip Country Details
LUMC RECRUITING Leiden South Holland 2333ZA Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field